立体定向放射外科术后激光消融:转移性脑肿瘤与放射性坏死患者的多中心前瞻性研究
LAASR是一项多中心前瞻性研究,评估激光间质热疗(LITT)消融用于立体定向放射外科术后影像学进展的脑转移患者。42例患者中19例为活检证实的放射性坏死、20例为复发肿瘤、3例无诊断,26周无进展生存率和总生存率分别为74%(20/27)和72%,多数病例手术安全。
要点
- 42例患者接受LITT消融,26周无进展生存率74%(20/27),总生存率72%。
- 30%受试者在术后12周内能够停用或减少类固醇用量。
- 放射性坏死患者较复发肿瘤或肿瘤进展患者有12周无进展生存和总生存优势。
核心结论
- 在这项入组患者几乎没有其他挽救治疗选择的研究中,LITT消融稳定了KPS评分、保持了生活质量和认知功能、具有减少类固醇用量的效果,并且在多数病例中安全实施。
研究设计与样本
- LAASR是一项多中心前瞻性研究,纳入立体定向放射外科治疗后影像学进展的脑转移患者,要求KPS评分≥60、年龄>18岁且符合手术条件。
- 共入组42例患者,其中19例为活检证实的放射性坏死、20例为复发肿瘤、3例无诊断;中位年龄60岁,64%为女性,中位基线KPS评分85。
- 主要结局为采用RANO-BM标准评估的局部无进展生存期,次要结局包括总生存期、手术安全性、神经认知功能和生活质量。
主要发现
- 平均病灶体积为6.4 cm3(范围0.4–38.6 cm3)。
- 复发肿瘤患者与放射性坏死患者的住院时间无显著差异(中位数分别为2.3天 vs 1.7天)。
- 26周时无进展生存率和总生存率分别为74%(20/27)和72%。
- 30%的受试者在术后12周内能够停用或减少类固醇用量。
- 两组的中位KPS评分、生活质量和神经认知结果在生存期间均无显著变化,两组不良事件相似且总体事件率无显著差异;放射性坏死患者较复发肿瘤或肿瘤进展患者有12周无进展生存和总生存优势。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Laser Ablation After Stereotactic Radiosurgery (LAASR) is a multicenter prospective study of laser interstitial thermal (LITT) ablation in patients with radiographic progression after stereotactic radiosurgery for brain metastases. METHODS: Patients with a Karnofsky Performance Scale (KPS) score ≥ 60, an age > 18 years, and surgical eligibility were included in this study. The primary outcome was local progression-free survival (PFS) assessed using the Response Assessment in Neuro-Oncology Brain Metastases (RANO-BM) criteria. Secondary outcomes were overall survival (OS), procedure safety, neurocognitive function, and quality of life. RESULTS: Forty-two patients—19 with biopsy-proven radiation necrosis, 20 with recurrent tumor, and 3 with no diagnosis—were enrolled. The median age was 60 years, 64% of the subjects were female, and the median baseline KPS score was 85. Mean lesion volume was 6.4 cm3 (range 0.4–38.6 cm3). There was no significant difference in length of stay between the recurrent tumor and radiation necrosis patients (median 2.3 vs 1.7 days, respectively). Progression-free survival and OS rates were 74% (20/27) and 72%, respectively, at 26 weeks. Thirty percent of subjects were able to stop or reduce steroid usage by 12 weeks after surgery. Median KPS score, quality of life, and neurocognitive results did not change significantly for either group over the duration of survival. Adverse events were also similar for the two groups, with no significant difference in the overall event rate. There was a 12-week PFS and OS advantage for the radiation necrosis patients compared with the recurrent tumor or tumor progression patients. CONCLUSIONS: In this study, in which enrolled patients had few alternative options for salvage treatment, LITT ablation stabilized the KPS score, preserved quality of life and cognition, had a steroid-sparing effect, and was performed safely in the majority of cases.
引用
- Ahluwalia M, Barnett GH, Deng D, et al. Laser ablation after stereotactic radiosurgery: a multicenter prospective study in patients with metastatic brain tumors and radiation necrosis. J Neurosurg. 2018. PMID: 29726782. doi:10.3171/2017.11.JNS171273
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。